Barclays Raises Privia Health (PRVA) PT to $24 on Strong Q1 Fee-for-Service Performance

On Tuesday, Barclays analyst Andrew Mok increased the price target on Privia Health Group Inc. (NASDAQ:PRVA) to $24 from $23, while maintaining an Equal Weight rating on the shares.

This revision follows Privia Health’s Q1 2025 report, which demonstrated steady progress with modest outperformance in its fee-for-service business.

A physician leveraging innovative technology to enable their patient care decisions.

In Q1, Privia Health reported a 12.8% year-over-year increase in Practice Collections and reached $798.6 million. This growth contributed to an overall 35.1% rise in Adjusted EBITDA to $26.9 million, and an expansion of the EBITDA margin by 4.6% year-over-year. The company also successfully managed its expenses and showcased a clear path to achieving 20% EBITDA growth by 2026.

Privia Health’s strategic expansion, which includes the entry into the Arizona market with a $95 million transaction for IMS, which is a large multi-specialty practice, is anticipated to be EBITDA positive by Q4 2025. This will further support the company’s fee-for-service operations. Privia Health Group Inc. (NASDAQ:PRVA) operates as a national physician-enablement company and collaborates with physician practices, health plans, and health systems. It offers technology and population health tools to enhance workflows.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.